Previous 10 | Next 10 |
NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated ...
CDMO, DCT, OTCQB:ELTP, MLKN, NEPT, NG, POWW, SGH For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close
Financials for Fiscal Year 2022 Ended March 31, 2022 will be released on June 29, 2022 NORTHVALE, NJ / ACCESSWIRE / June 23, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today ...
NORTHVALE, NJ / ACCESSWIRE / May 11, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer (CF...
Elite Pharma (ELTP +5.6%) said it received approval from the U.S. Food and Drug Administration for doxycycline hyclate 100 mg tablets to treat a wide variety of bacterial infections. The company's doxycycline hyclate is a generic version of Pfizer's Vibramycin. The drug is co-develo...
NORTHVALE, NJ / ACCESSWIRE / April 4, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that together with Elite's co-development partner, Praxgen Pharmaceuticals LLC, formerly Sun...
Elite Pharmaceuticals, Inc. (ELTP) Q3 2022 Results Conference Call February 15, 2022 11:30 AM ET Company Participants Nasrat Hakim - President and CEO Marc Bregman - CFO Conference Call Participants Presentation Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuti...
Elite Pharmaceuticals press release (OTCQB:ELTP): FQ3 GAAP EPS of $0.00. Revenue of $8.97M (+48.3% Y/Y). 10Q For further details see: Elite Pharmaceuticals GAAP EPS of $0.00, revenue of $8.97M
Conference Call Scheduled for Tuesday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the third q...
AAP, AEMD, AMKR, ANET, ASYS, BKD, CAR, CIDM, CLR, OTCQB:ELTP, OTCQB:GAXY, HE, IBIO, KRG, MEDP, OMCL, OTTR, POWW, PRI, SCI, SRC, STEM, TNET, VNO, WTER, ZD For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close
News, Short Squeeze, Breakout and More Instantly...
Elite Pharmaceuticals Inc. Company Name:
ELTP Stock Symbol:
OTCMKTS Market:
Elite Pharmaceuticals Inc. Website:
Financials for Fiscal Year 2024 Ended March 31, 2024 will be released on July 1, 2024 Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced to...